founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c
Company profile
Ticker
ANAB
Exchange
Website
CEO
Hamza Suria
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ANAPTYS BIOSCIENCES INC, ANAPTYSBIO INC
SEC CIK
Corporate docs
Subsidiaries
AnaptysBio Pty Ltd ...
ANAB stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
S-8
Registration of securities for employees
11 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
8-K
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
11 Mar 24
8-K
Results of Operations and Financial Condition
5 Jan 24
8-K
Entry into a Material Definitive Agreement
27 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
2 Nov 23
Latest ownership filings
4
Daniel Faga
26 Mar 24
4
ERIC J LOUMEAU
21 Feb 24
144
Notice of proposed sale of securities
16 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
DENNIS MULROY
1 Feb 24
144
Notice of proposed sale of securities
30 Jan 24
SC 13G/A
BlackRock Inc.
26 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.30 mm | 26.30 mm | 26.30 mm | 26.30 mm | 26.30 mm | 26.30 mm |
Cash burn (monthly) | 2.97 mm | 2.69 mm | 12.58 mm | 12.35 mm | 12.16 mm | 8.09 mm |
Cash used (since last report) | 20.52 mm | 18.57 mm | 86.88 mm | 85.34 mm | 83.99 mm | 55.92 mm |
Cash remaining | 5.78 mm | 7.73 mm | -60.59 mm | -59.05 mm | -57.69 mm | -29.62 mm |
Runway (months of cash) | 1.9 | 2.9 | -4.8 | -4.8 | -4.7 | -3.7 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 119 |
Opened positions | 14 |
Closed positions | 14 |
Increased positions | 34 |
Reduced positions | 38 |
13F shares | Current |
---|---|
Total value | 542.23 bn |
Total shares | 42.13 mm |
Total puts | 59.50 k |
Total calls | 56.00 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
EcoR1 Capital | 7.52 mm | $135.08 bn |
EcoR1 Capital Fund | 7.15 mm | $139.53 mm |
Tang Capital Partners | 2.63 mm | $56.52 mm |
Tang Capital Management | 1.95 mm | $35.03 bn |
BLK Blackrock | 1.82 mm | $32.76 bn |
Vanguard | 1.70 mm | $30.58 bn |
Deep Track Capital | 1.35 mm | $24.17 bn |
Boxer Capital | 1.30 mm | $23.35 bn |
Flynn James E | 1.16 mm | $0.00 |
Braidwell | 1.05 mm | $18.85 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Mar 24 | Daniel Faga | Common Stock | Payment of exercise | Dispose F | No | No | 21.6 | 347,441 | 7.50 mm | 401,646 |
25 Mar 24 | Daniel Faga | Common Stock | Sell | Dispose S | No | No | 21.4225 | 3,000 | 64.27 k | 749,087 |
22 Mar 24 | Daniel Faga | Common Stock | Sell | Dispose S | No | No | 22.7846 | 145,940 | 3.33 mm | 752,087 |
30 Jan 24 | Mulroy Dennis | Common Stock | Sell | Dispose S | No | Yes | 23.6298 | 3,065 | 72.43 k | 964 |
8 Jan 24 | Daniel Faga | Common Stock | Sell | Dispose S | No | No | 21.81 | 6,866 | 149.75 k | 898,027 |
8 Jan 24 | Mulroy Dennis | Common Stock | Sell | Dispose S | No | No | 21.81 | 2,180 | 47.55 k | 4,029 |
8 Jan 24 | Loumeau Eric J | Common Stock | Sell | Dispose S | No | No | 21.81 | 2,305 | 50.27 k | 3,240 |
6 Jan 24 | Daniel Faga | Common Stock | Option exercise | Acquire M | No | No | 0 | 17,850 | 0.00 | 904,893 |
6 Jan 24 | Daniel Faga | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 17,850 | 0.00 | 53,550 |
6 Jan 24 | Mulroy Dennis | Common Stock | Option exercise | Acquire M | No | No | 0 | 5,245 | 0.00 | 6,209 |
News
Leerink Partners Initiates Coverage On AnaptysBio with Outperform Rating, Announces Price Target of $47
16 Apr 24
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
11 Apr 24
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
11 Apr 24
Wells Fargo Initiates Coverage On AnaptysBio with Overweight Rating, Announces Price Target of $56
11 Apr 24
Unveiling 4 Analyst Insights On AnaptysBio
1 Apr 24